Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. ViroGates A/S
  6. News
  7. Summary
    VIRO   DK0061030574

VIROGATES A/S

(VIRO)
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Elevated preoperative suPAR is a strong and independent risk marker for postoperative complications in patients undergoing major noncardiac surgery

11/05/2021 | 07:08am EST

A recent prospective observational study has investigated whether suPAR (soluble urokinase plasminogen activator receptor), can aid in identifying patients at high risk for postoperative complications, morbidity, and mortality.

Conclusion

Preoperative suPAR provided strong and independent predictive value on postoperative complications in White patients undergoing major noncardiac surgery.

Results

EDTA (Ethylenediaminetetraacetic Acid) blood was collected from adult (≥18 years old) White patients scheduled for major noncardiac surgery with an expected duration ≥2 hours under general anesthesia. Plasma suPAR levels were determined using the suPARnostic quick triage lateral flow assay. The primary endpoint was postoperative complications defined as the presence of any complication and/or admission to intensive care unit and/or mortality within the first 90 postoperative days.

Method

Preoperative suPAR had an odds ratio of 1.50 for every ng/mL increase. When including age, sex, American Society of Anesthesiologists score, C-reactive protein, and grouped suPAR in multivariate analysis, patients with suPAR levels between 5.5 and 10 ng/mL had an odds ratio of 11.2, and patients with suPAR >10 ng/mL had an odds ratio of 19.9 compared to patients with suPAR ≤5.5 ng/mL, respectively.

Disclaimer

ViroGates A/S published this content on 04 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 November 2021 12:07:01 UTC.


ę Publicnow 2021
All news about VIROGATES A/S
01/11NATURE MEDICINE PUBLICATION : Early anakinra treatment for COVID-19 guided by suPAR saves ..
PU
2021ViroGates publishes the financial calendar for 2022
AQ
2021ViroGates on positive EMA opinion regarding suPAR-guided anakinra treatment (Video)
AQ
2021ViroGates announces a positive opinion from the CHMP of the EMA for suPAR-guided anakin..
AQ
2021ViroGates Announces Positive Opinion from the CHMP of the EMA for suPAR-Guided Anakinra..
CI
2021VIROGATES A/S : SuPAR independently predicts severity and length of hospitalisation in pat..
PU
2021ViroGates announces a development, supply and collaboration agreement with Italy-based ..
AQ
2021FRONTIERS IN IMMUNOLOGY PUBLICATION : Soluble Urokinase Plasminogen Activator Receptor (su..
PU
2021ViroGates awarded a 2.8 DKKm Innobooster grant by The Innovation Fund Denmark to finali..
AQ
2021NATURE MEDICINE PUBLICATION : Early anakinra treatment for COVID-19 guided by suPAR saves ..
PU
More news
Financials
Sales 2020 5,35 M 0,82 M 0,82 M
Net income 2020 -18,7 M -2,87 M -2,87 M
Net cash 2020 33,5 M 5,14 M 5,14 M
P/E ratio 2020 -13,4x
Yield 2020 -
Capitalization 485 M 74,4 M 74,4 M
EV / Sales 2019 17,5x
EV / Sales 2020 41,3x
Nbr of Employees 14
Free-Float -
Chart VIROGATES A/S
Duration : Period :
ViroGates A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIROGATES A/S
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Managers and Directors
Jakob Knudsen Chief Executive Officer
Mark Christian Hvidberg da Silva Chief Financial Officer
Lars Kongsbak Chairman
Jesper Eugen-Olsen Chief Scientific Officer
J÷rgen Axel Thorball Director
Sector and Competitors